Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature
- PMID: 35160187
- PMCID: PMC8836768
- DOI: 10.3390/jcm11030739
Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature
Abstract
Leukocytoclastic vasculitis (LCV) is a rare extraintestinal manifestation (EIM) of ulcerative colitis (UC). Observations about its association with UC stem from case reports and small case series. Due to its rarity, more rigorous cross-sectional studies are scarce and difficult to conduct. The aim of this systematic review was to synthetize the knowledge on this association by reviewing published literature in the form of both case reports and case series; and report the findings according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In contrast to LCV in Chron disease (CD), which occurs secondary to biologic therapies used for its treatment, LCV in UC is a true reactive skin manifestation. Both genders are equally affected. Palpable purpura (41%) and erythematous plaques (27%) are the most common clinical manifestations. In 41% of patients, the rash is painful, and the lower extremities are most commonly involved (73%). Systemic symptoms such as fever, arthralgias, fatigue, and malaise are seen in 60% of patients. Unlike previous reports, we found that LCV more commonly occurs after the UC diagnosis (59%), and 68% of patients have active intestinal disease at the time of LCV diagnosis. Antineutrophil cytoplasmic antibody (ANCA) is positive in 41% of patients, and 36% of patients have other EIMs present concomitantly with LCV. The majority of patients were treated with corticosteroids (77%), and two (10%) required colectomy to control UC and LCV symptoms. Aside from one patient who died from unrelated causes, all others survived with their rash typically resolving without scarring (82%).
Keywords: Crohn’s disease; hypersensitivity vasculitis; leukocytoclastic vasculitis; ulcerative colitis; vasculitis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Leukocytoclastic vasculitis as a rare dermatologic manifestation of Crohn's disease mimicking cellulitis: a case report.BMC Gastroenterol. 2020 Jul 29;20(1):240. doi: 10.1186/s12876-020-01371-3. BMC Gastroenterol. 2020. PMID: 32727390 Free PMC article.
-
Leukocytoclastic Vasculitis as an Extraintestinal Manifestation of Crohn's Disease.Case Rep Gastroenterol. 2021 Sep 23;15(3):825-831. doi: 10.1159/000519003. eCollection 2021 Sep-Dec. Case Rep Gastroenterol. 2021. PMID: 34720830 Free PMC article.
-
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5. Acta Dermatovenerol Croat. 2016. PMID: 27149138
-
Diagnosis and management of leukocytoclastic vasculitis.Intern Emerg Med. 2021 Jun;16(4):831-841. doi: 10.1007/s11739-021-02688-x. Epub 2021 Mar 13. Intern Emerg Med. 2021. PMID: 33713282 Free PMC article. Review.
-
Management of leukocytoclastic vasculitis.J Dermatolog Treat. 2005;16(4):193-206. doi: 10.1080/09546630500277971. J Dermatolog Treat. 2005. PMID: 16249140 Review.
Cited by
-
Co-occurrence of Meningioma and Intracranial Aneurysm: A Systematic Review.Cureus. 2024 Jan 25;16(1):e52919. doi: 10.7759/cureus.52919. eCollection 2024 Jan. Cureus. 2024. PMID: 38406094 Free PMC article. Review.
-
Atypical Immunoglobulin A Vasculitis in a Pediatric Patient With Ulcerative Colitis.ACG Case Rep J. 2023 Sep 5;10(9):e01145. doi: 10.14309/crj.0000000000001145. eCollection 2023 Sep. ACG Case Rep J. 2023. PMID: 37681212 Free PMC article.
-
Pyoderma gangrenosum-like lesions in the setting of IgA cutaneous vasculitis: Favourable response to adalimumab.Skin Health Dis. 2024 Feb 6;4(2):e347. doi: 10.1002/ski2.347. eCollection 2024 Apr. Skin Health Dis. 2024. PMID: 38577052 Free PMC article.
-
Cutaneous small vessel vasculitis in the COVID-19 era: a systematic review.Skin Health Dis. 2025 Apr 22;5(2):114-123. doi: 10.1093/skinhd/vzaf004. eCollection 2025 Apr. Skin Health Dis. 2025. PMID: 40365256 Free PMC article. Review.
-
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project.Biomedicines. 2022 Dec 18;10(12):3280. doi: 10.3390/biomedicines10123280. Biomedicines. 2022. PMID: 36552036 Free PMC article.
References
-
- Sy A., Khalidi N., Dehghan N., Barra L., Carette S., Cuthbertson D., Hoffman G.S., Koening C.L., Langford C.A., McAlear C., et al. Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Semin. Arthritis Rheum. 2016;45:475–482. doi: 10.1016/j.semarthrit.2015.07.006. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources